| Autor: |
Clements, Karen M., Peltz, Gerson, Faries, Douglas E., Lang, Kathleen, Nyambose, Joshua, Earle, Craig C., Sugarman, Katherine P., Taylor, Douglas C. A., Thompson, David, Marciniak, Martin D. |
| Zdroj: |
Chemotherapy Research & Practice; 2010, p1-8, 8p, 1 Diagram, 2 Charts, 4 Graphs |
| Abstrakt: |
Chemotherapy regimens may have differential efficacy by histology in nonsmall cell lung cancer (NSCLC). We examined the impact of histology on survival of patients (N = 2,644) with stage IIIB/IV NSCLC who received first-line cisplatin/carboplatin plus gemcitabine (C/C+G) and cisplatin/carboplatin plus a taxane (C/C+T) identified retrospectively in the SEER cancer registry (1997-2002). Patients with squamous and nonsquamous cell carcinoma survived 8.5 months and 8.1 months, respectively (P = .018). No statistically significant difference was observed in survival between C/C+G and C/C+T in both histologies. Adjusting for clinical and demographic characteristics, the effect of treatment regimen on survival did not differ by histology (P for interaction = .257). There was no statistically significant difference in hazard of death by histology in both groups. These results contrast the predictive role of histology and improved survival outcomes observed for cisplatin-pemetrexed regimens in advanced nonsquamous NSCLC. [ABSTRACT FROM AUTHOR] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
